Tesla, Inc. vs Zoetis Inc — how do they compare? Tesla, Inc. trades at $383.63 (market cap $1.48T), while Zoetis Inc trades at $74.57 (market cap $30.20B). The key difference: Tesla, Inc. is far larger — about 49× Zoetis Inc's market cap, and Zoetis Inc pays a 2.9% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tesla, Inc. for 88 Days and Zoetis Inc for 70 Days on average.
| TSLA | ZTS | |
|---|---|---|
Market Cap | $1.48T | $30.20B |
Volume | 28,215,427 | 6,175,327 |
Sector | Consumer Cyclical | Health |
52-Week High | $489.88 | $147.53 |
52-Week Low | $298.16 | $69.09 |
Typical Hold Time | 88 Days | 70 Days |
Enterprise Value | $1.45T | $37.76B |
Dividend Yield | — | 2.9% |
Signals from Pluang's Aura AI — not financial advice
Tesla trades at $382.89, up 1.4% with a bullish technical signal from moving averages. The company shows mixed fundamentals with declining profit margins (3.67% net income margin) despite recent earnings beats, while valuation ratios remain elevated (P/E 347). Recent news highlights regulatory approval for driver-assistance software in Europe and a potential cheaper EV model, though Q2 2026 earnings missed expectations. Cash flow trends show consistent operational strength but heavy investment outflows.
Tesla's outlook balances innovation leadership in autonomy and energy against near-term execution risks and rich valuations. The consensus price target of $441 suggests 15% upside, but investors face volatility from competitive pressures and reliance on future technology adoption. The stock's performance hinges on delivering growth beyond traditional automotive segments.
Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.
The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →